Abbott Laboratories (NYSE:ABT)
| 110.52 Delayed Data As of Aug 11 |  +0.03 / +0.03%Today’s Change | 101.24 Today|||52-Week Range 142.60 | -21.47% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | 563.0M | 654.0M | 672.0M | 1.0B | |
| Depreciation | 813.0M | 763.0M | 753.0M | 751.0M | ||
| Total Other Cash Flow | 83.0M | 374.0M | 226.0M | 114.0M | ||
| Funds From Operations | 1.5B | 1.8B | 1.7B | 1.9B | ||
| Funds From/For Other Operating Expenses | -724.0M | 26.0M | 939.0M | 811.0M | ||
| Net Cash Flow - Operating Activities | 2.2B | 1.8B | 712.0M | 1.1B | ||
| Investing | Increase In Investments | 19.0M | -108.0M | -- | -- | |
| Decrease In Investments | 0.00 | 73.0M | 2.0M | 0.00 | ||
| Capital Expenditures | -354.0M | -467.0M | -335.0M | -468.0M | ||
| Fixed Asset Disposal | 0.00 | 0.00 | -- | 48.0M | ||
| Net Assets From Acquisitions | 0.00 | 0.00 | -78.0M | -82.0M | ||
| Other Investing - Sources | 12.0M | 6.0M | 15.0M | 4.0M | ||
| Net Cash Flow Investing | -323.0M | -496.0M | -396.0M | -498.0M | ||
| Financing | Short Term Borrowings | -118.0M | -48.0M | 13.0M | 27.0M | |
| Long Term Borrowings | 4.0B | -2.0M | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -999.0M | -4.2B | -500.0M | -21.0M | ||
| Net Proceeds Stock Sale | 74.0M | 27.0M | 127.0M | 117.0M | ||
| Common Preferred Redeemed | -3.0M | -104.0M | -217.0M | -4.0M | ||
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | -494.0M | -495.0M | -565.0M | -568.0M | ||
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | 2.5B | -4.8B | -1.1B | -449.0M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -27.0M | -18.0M | 4.0M | 2.0M | |
| Net Change In Cash | 4.3B | -3.5B | -826.0M | 113.0M | ||
